JP2024063016A5 - - Google Patents
Info
- Publication number
- JP2024063016A5 JP2024063016A5 JP2024017576A JP2024017576A JP2024063016A5 JP 2024063016 A5 JP2024063016 A5 JP 2024063016A5 JP 2024017576 A JP2024017576 A JP 2024017576A JP 2024017576 A JP2024017576 A JP 2024017576A JP 2024063016 A5 JP2024063016 A5 JP 2024063016A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- antagonist
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802487.7A GB201802487D0 (en) | 2018-02-15 | 2018-02-15 | Cytokine combination therapy |
| GB1802487.7 | 2018-02-15 | ||
| PCT/EP2019/053890 WO2019158728A1 (en) | 2018-02-15 | 2019-02-15 | Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r |
| JP2020543512A JP7808430B2 (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543512A Division JP7808430B2 (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024063016A JP2024063016A (ja) | 2024-05-10 |
| JP2024063016A5 true JP2024063016A5 (https=) | 2026-04-14 |
Family
ID=61783635
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543512A Active JP7808430B2 (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
| JP2024017576A Pending JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543512A Active JP7808430B2 (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12030949B2 (https=) |
| EP (1) | EP3752529A1 (https=) |
| JP (2) | JP7808430B2 (https=) |
| CN (1) | CN112041342B (https=) |
| AU (1) | AU2019221627B2 (https=) |
| CA (1) | CA3088734A1 (https=) |
| GB (1) | GB201802487D0 (https=) |
| IL (1) | IL276344A (https=) |
| WO (1) | WO2019158728A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| CN111825766B (zh) * | 2019-10-31 | 2021-05-11 | 上海洛启生物医药技术有限公司 | 抗il-4r单域抗体及其应用 |
| EP4165066A4 (en) * | 2020-06-12 | 2024-08-14 | Beijing Vdjbio Co., Ltd. | FUSION POLYPEPTIDE |
| JP7743500B2 (ja) | 2020-08-05 | 2025-09-24 | シンセカイン インコーポレイテッド | Ｉｌ１０受容体結合性分子および使用方法 |
| US12018085B2 (en) | 2020-08-05 | 2024-06-25 | Synthekine, Inc. | Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases |
| WO2022032006A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb binding molecules and methods of use |
| WO2022032045A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | IL10Rα/IL2Rγ SYNTHETIC CYTOKINES |
| CN117903303A (zh) * | 2020-08-20 | 2024-04-19 | 南京融捷康生物科技有限公司 | Il-5的结合分子及其应用 |
| KR102697769B1 (ko) * | 2020-09-14 | 2024-08-23 | 아주대학교산학협력단 | 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도 |
| CN113307870B (zh) * | 2020-10-30 | 2022-12-23 | 上海洛启生物医药技术有限公司 | 抗il5纳米抗体及其应用 |
| CN114605539B (zh) * | 2020-12-09 | 2024-01-02 | 南京融捷康生物科技有限公司 | 人源化的抗IL-4Rα单域抗体及其应用 |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| CN114805572B (zh) * | 2021-01-22 | 2022-12-13 | 上海济煜医药科技有限公司 | 抗原结合蛋白及其应用 |
| CA3239182A1 (en) * | 2022-05-23 | 2023-11-30 | Zhipeng SU | Stable antibody preparation |
| CN116606375B (zh) * | 2023-07-03 | 2025-10-03 | 珠海瑞思普利医药科技有限公司 | 抗人白介素5纳米抗体及其应用 |
| WO2026020024A1 (en) * | 2024-07-19 | 2026-01-22 | Bambusa Therapeutics, Inc. | Multispecific binding agents and uses thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| WO2009040562A1 (en) | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| US20110008326A1 (en) | 2008-04-02 | 2011-01-13 | Oliver Hill | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| HRP20170374T1 (hr) | 2008-09-26 | 2017-05-05 | Ucb Biopharma Sprl | Biološki proizvodi |
| BRPI1014449A2 (pt) | 2009-04-07 | 2017-06-27 | Roche Glycart Ag | anticorpos biespecíficos anti-erbb-2/ anti-c-met. |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| EP2824111B1 (en) * | 2010-04-30 | 2017-03-22 | Alexion Pharmaceuticals, Inc. | Anti-C5A Antibodies and Methods for Using the Antibodies |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| US9683052B2 (en) | 2011-03-25 | 2017-06-20 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| GB2504139B (en) | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
| PT2825559T (pt) | 2012-03-13 | 2019-06-07 | Novimmune Sa | Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo |
| DK2847231T3 (da) | 2012-05-10 | 2019-10-14 | Bioatla Llc | Multispecifikke monoklonale antistoffer |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP3878964A1 (en) | 2012-11-27 | 2021-09-15 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| US10047163B2 (en) | 2013-02-08 | 2018-08-14 | Abbvie Stemcentrx Llc | Multispecific constructs |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
| AU2014284235C1 (en) * | 2013-06-21 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods for treating nasal polyposis by administering an IL-4R antagonist |
| US11261262B2 (en) | 2013-09-03 | 2022-03-01 | Novimmune Sa | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN105814082A (zh) | 2013-09-26 | 2016-07-27 | 埃博灵克斯股份有限公司 | 双特异性纳米抗体 |
| KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| RU2609627C2 (ru) | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| US20160272706A1 (en) * | 2015-01-12 | 2016-09-22 | Medimmune Limited | Il-13 binding proteins and uses thereof |
| MA41375A (fr) | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
| IL262241B2 (en) | 2016-04-13 | 2024-05-01 | Sanofi Sa | Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases |
| SI3468586T1 (sl) | 2016-06-14 | 2025-01-31 | Xencor, Inc. | Bispecifična protitelesa za zaviralce kontrolnih točk |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| GB201707484D0 (en) | 2017-05-10 | 2017-06-21 | Argenx Bvba | Method of preparing ph-dependent antibodies |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
-
2018
- 2018-02-15 GB GBGB1802487.7A patent/GB201802487D0/en not_active Ceased
-
2019
- 2019-02-15 CA CA3088734A patent/CA3088734A1/en active Pending
- 2019-02-15 CN CN201980025923.3A patent/CN112041342B/zh active Active
- 2019-02-15 US US16/966,237 patent/US12030949B2/en active Active
- 2019-02-15 JP JP2020543512A patent/JP7808430B2/ja active Active
- 2019-02-15 WO PCT/EP2019/053890 patent/WO2019158728A1/en not_active Ceased
- 2019-02-15 AU AU2019221627A patent/AU2019221627B2/en active Active
- 2019-02-15 EP EP19715814.0A patent/EP3752529A1/en active Pending
-
2020
- 2020-07-28 IL IL276344A patent/IL276344A/en unknown
-
2024
- 2024-02-08 JP JP2024017576A patent/JP2024063016A/ja active Pending
- 2024-06-28 US US18/758,267 patent/US20240352138A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024063016A5 (https=) | ||
| JP2021513974A5 (https=) | ||
| AU2022241522B2 (en) | Bispecific antibody to a-syn/igf1r and use thereof | |
| AU2023203440A1 (en) | Antibodies that specifically bind to TL1A | |
| JP2023113686A (ja) | ｐＨ依存的抗体の調製方法 | |
| JPWO2019158728A5 (https=) | ||
| JP2010538608A5 (https=) | ||
| WO2009052081A4 (en) | Antibodies that bind il-4 and/or il-13 and their uses | |
| BR112013016235B1 (pt) | Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica | |
| JP2018509153A (ja) | Ｔｓｌｐ結合タンパク質 | |
| JP6898251B2 (ja) | 組換え抗体分子の単量体化方法 | |
| CA2727992A1 (en) | Stable and soluble antibodies inhibiting tnf.alpha. | |
| JP2019527194A5 (https=) | ||
| JP2014525736A (ja) | ＩｇＥに対する免疫グロブリン単一可変ドメイン | |
| AU2023202595B2 (en) | BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF | |
| WO2024120479A1 (zh) | 一种针对IgE的抗体或其抗原结合片段以及Fc变体 | |
| CA3192208A1 (en) | Anti-par-2 antibodies and methods of use thereof | |
| CA3096791A1 (en) | Cell engaging binding molecules | |
| JPWO2022111425A5 (https=) | ||
| TW202525846A (zh) | 抗ｉｌ—１３多特異性抗體構築體及其用途 | |
| KR20250042149A (ko) | Ige-fceri의 디스플레이서 | |
| JPWO2021162098A5 (https=) | ||
| US20260028396A1 (en) | Anti-myostatin antibodies and methods | |
| US11981727B2 (en) | Monospecific and bispecific antibodies and antigen binding fragments thereof | |
| US20240117056A1 (en) | Epidermal growth factor receptor variant iii antibodies |